<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.48.0">
<page number="1" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="0" size="10" family="Times" color="#231f20"/>
	<fontspec id="1" size="16" family="Times" color="#231f20"/>
	<fontspec id="2" size="14" family="Times" color="#231f20"/>
	<fontspec id="3" size="14" family="Times" color="#231f20"/>
	<fontspec id="4" size="13" family="Times" color="#231f20"/>
	<fontspec id="5" size="22" family="Times" color="#231f20"/>
	<fontspec id="6" size="25" family="Times" color="#231f20"/>
	<fontspec id="7" size="7" family="Times" color="#231f20"/>
	<fontspec id="8" size="14" family="Times" color="#231f20"/>
<text top="108" left="106" width="210" height="12" font="0">Archives of the Balkan Medical Union</text>
<text top="122" left="106" width="226" height="12" font="0">Copyright © 2019 Balkan Medical Union</text>
<text top="108" left="635" width="151" height="12" font="0">vol. 54, no. 2, pp. 330-333</text>
<text top="122" left="728" width="59" height="12" font="0">June 2019</text>
<text top="599" left="457" width="12" height="18" font="1">R</text>
<text top="603" left="469" width="43" height="13" font="0">ÉSUMÉ</text>
<text top="634" left="457" width="329" height="19" font="2"><b>Transplantation hépatique pour des métastases hépa-</b></text>
<text top="653" left="457" width="334" height="19" font="2"><b>tiques non résécables d’un cancer colorectal – revue </b></text>
<text top="672" left="457" width="98" height="19" font="2"><b>de la littérature</b></text>
<text top="709" left="457" width="334" height="19" font="3">Le cancer colorectal est l’une des tumeurs malignes </text>
<text top="728" left="457" width="335" height="19" font="3">les plus répandues dans le monde, associée à un </text>
<text top="747" left="457" width="334" height="19" font="3">risque accru de développer des métastases au niveau </text>
<text top="766" left="457" width="329" height="19" font="3">du foie. D’un point de vue historique, le développe-</text>
<text top="784" left="457" width="329" height="19" font="3">ment de métastases hépatiques colorectales a été as-</text>
<text top="803" left="457" width="334" height="19" font="3">socié à des taux de survie extrêmement médiocres. </text>
<text top="822" left="457" width="333" height="19" font="3">L’amélioration des techniques chirurgicales ainsi que </text>
<text top="841" left="457" width="333" height="19" font="3">la gestion périopératoire, associées au développement </text>
<text top="859" left="457" width="330" height="19" font="3">de nouveaux agents chimiothérapeutiques, ont per-</text>
<text top="878" left="457" width="334" height="19" font="3">mis d’améliorer la survie. Cependant, dans certains </text>
<text top="897" left="457" width="329" height="19" font="3">cas de métastases hépatiques inopérables, l’associa-</text>
<text top="916" left="457" width="335" height="19" font="3">tion de la chimiothérapie à la résection n’est plus </text>
<text top="934" left="457" width="333" height="19" font="3">possible en raison de l’étendue locale de la maladie. </text>
<text top="953" left="457" width="334" height="19" font="3">Dans de tels cas, la transplantation hépatique a été </text>
<text top="972" left="457" width="333" height="19" font="3">proposée avec des résultats prometteurs. Cependant, </text>
<text top="991" left="457" width="336" height="19" font="3">cette stratégie thérapeutique n’est indiquée que </text>
<text top="1010" left="457" width="329" height="19" font="3">lorsque l’absence de maladie extrahépatique est do-</text>
<text top="1028" left="457" width="333" height="19" font="3">cumentée. Il s’agit d’une étude récapitulative des plus </text>
<text top="1047" left="457" width="333" height="19" font="3">grandes études portant sur la transplantation du foie </text>
<text top="599" left="106" width="12" height="18" font="1">A</text>
<text top="603" left="118" width="55" height="13" font="0">BSTRACT</text>
<text top="634" left="106" width="333" height="19" font="3">Colorectal cancer represents one of the most common </text>
<text top="653" left="106" width="335" height="19" font="3">malignancies reported worldwide, associated with </text>
<text top="672" left="106" width="334" height="19" font="3">an increased risk of hepatic metastases development. </text>
<text top="691" left="106" width="334" height="19" font="3">Historically, the development of liver metastases from </text>
<text top="709" left="106" width="333" height="19" font="3">colorectal cancer has been associated with extremely </text>
<text top="728" left="106" width="334" height="19" font="3">poor rates in terms of survival. Improvement of the </text>
<text top="747" left="106" width="333" height="19" font="3">surgical techniques, as well as of the perioperative </text>
<text top="766" left="106" width="335" height="19" font="3">outcomes, in association with the development of </text>
<text top="784" left="106" width="333" height="19" font="3">new chemotherapeutic agents lead to a better survival; </text>
<text top="803" left="106" width="329" height="19" font="3">however, in certain cases with unresectable liver metas-</text>
<text top="822" left="106" width="334" height="19" font="3">tases, association of chemotherapy and resection can </text>
<text top="841" left="106" width="333" height="19" font="3">be no longer feasible due to the extent of the disease. </text>
<text top="859" left="106" width="334" height="19" font="3">In such cases liver transplantation has been proposed </text>
<text top="878" left="106" width="330" height="19" font="3">with promising results. However, this therapeutic strat-</text>
<text top="897" left="106" width="333" height="19" font="3">egy is only indicated when the absence of extrahepatic </text>
<text top="916" left="106" width="334" height="19" font="3">disease is documented. This is a literature review of </text>
<text top="935" left="106" width="334" height="19" font="3">the largest studies which focused on the topic of liver </text>
<text top="953" left="106" width="333" height="19" font="3">transplantation for unresectable liver metastases from </text>
<text top="972" left="106" width="106" height="19" font="3">colorectal cancer.</text>
<text top="1013" left="106" width="74" height="16" font="4">Keywords: </text>
<text top="1009" left="184" width="252" height="19" font="3">colorectal cancer, hepatic metastases, ex-</text>
<text top="1028" left="106" width="214" height="19" font="3">trahepatic disease, liver transplant.</text>
<text top="200" left="703" width="83" height="24" font="5">REVIEW</text>
<text top="311" left="106" width="571" height="27" font="6">LIVER TRANSPLANTATION FOR UNRESECTABLE </text>
<text top="341" left="106" width="640" height="27" font="6">HEPATIC METASTASES FROM COLORECTAL CANCER: </text>
<text top="371" left="106" width="251" height="27" font="6">LITERATURE REVIEW</text>
<text top="423" left="106" width="153" height="17" font="3">Nicolae BACALBASA</text>
<text top="422" left="259" width="27" height="10" font="7">1,2,3 </text>
<text top="423" left="294" width="119" height="17" font="3">, Irina BALESCU</text>
<text top="422" left="413" width="6" height="10" font="7">4</text>
<text top="423" left="419" width="119" height="17" font="3">, Mihaela VILCU</text>
<text top="422" left="538" width="15" height="10" font="7">2,3</text>
<text top="423" left="553" width="129" height="17" font="3">, Iulian BREZEAN</text>
<text top="422" left="682" width="15" height="10" font="7">2,3</text>
<text top="447" left="106" width="5" height="11" font="7">1</text>
<text top="446" left="111" width="625" height="19" font="3"> Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania</text>
<text top="466" left="106" width="5" height="11" font="7">2</text>
<text top="465" left="111" width="486" height="19" font="3"> „Carol Davila“ University of Medicine and Pharmacy, Bucharest, Romania</text>
<text top="485" left="106" width="5" height="11" font="7">3</text>
<text top="484" left="111" width="379" height="19" font="3"> „Ion Cantacuzino“ Clinical Hospital  , Bucharest, Romania</text>
<text top="503" left="106" width="5" height="11" font="7">4</text>
<text top="503" left="111" width="329" height="19" font="3"> Ponderas Academic Hospital, Bucharest, Romania</text>
<text top="521" left="514" width="273" height="19" font="8"><i>Received 25 Mar 2019, Accepted 08 May 2019</i></text>
<text top="545" left="550" width="236" height="12" font="0">https://doi.org/10.31688/ABMU.2019.54.2.17</text>
<text top="1113" left="143" width="167" height="13" font="0"> Address for correspondence:  </text>
<text top="1113" left="348" width="108" height="13" font="0"> Nicolae BACALBASA</text>
<text top="1131" left="348" width="388" height="13" font="0">Carol Davila“ University of Medicine and Pharmacy, Bucharest, Romania</text>
<text top="1148" left="348" width="333" height="13" font="0">Email: nicolae_bacalbasa@yahoo.ro, Phone 0040723540426</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="9" size="11" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="9">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="9">June </text>
<text top="1182" left="693" width="94" height="14" font="9">2019 / 331</text>
<text top="277" left="106" width="5" height="18" font="1">I</text>
<text top="281" left="112" width="85" height="13" font="0">NTRODUCTION</text>
<text top="312" left="136" width="305" height="19" font="3">Colorectal cancer represents one of the most </text>
<text top="331" left="106" width="333" height="19" font="3">commonly  reported  malignancies  worldwide. </text>
<text top="350" left="106" width="334" height="19" font="3">Although this neoplastic process is rather facile to </text>
<text top="369" left="106" width="335" height="19" font="3">be diagnosed once the lower endoscopy has been </text>
<text top="388" left="106" width="329" height="19" font="3">widely performed, up to 25% of cases will be diag-</text>
<text top="407" left="106" width="333" height="19" font="3">nosed in advanced stages of the disease, when liver </text>
<text top="426" left="106" width="334" height="19" font="3">metastases are already present. Moreover, up to half </text>
<text top="444" left="106" width="334" height="19" font="3">of the patients diagnosed with this malignancy will </text>
<text top="463" left="106" width="329" height="19" font="3">develop liver metastases at a certain point of the evo-</text>
<text top="482" left="106" width="334" height="19" font="3">lution of their disease. Once the distant metastases </text>
<text top="501" left="106" width="335" height="19" font="3">develop, the overall prognosis becomes extremely </text>
<text top="520" left="106" width="333" height="19" font="3">poor, the five years overall survival being of less than </text>
<text top="539" left="106" width="334" height="19" font="3">10% in the absence of a radical therapeutic strategy. </text>
<text top="557" left="106" width="335" height="19" font="3">However, due to the improvement of the surgical </text>
<text top="576" left="106" width="333" height="19" font="3">techniques, as well as due to the improvement of the </text>
<text top="595" left="106" width="330" height="19" font="3">perioperative management of such cases, liver resec-</text>
<text top="614" left="106" width="329" height="19" font="3">tion of the metastatic disease in association with sys-</text>
<text top="633" left="106" width="333" height="19" font="3">temic chemotherapy have been proposed with good </text>
<text top="652" left="106" width="334" height="19" font="3">results, the five years overall survival rate increasing </text>
<text top="671" left="106" width="330" height="19" font="3">at up to 45%. Unfortunately, not all the patients di-</text>
<text top="689" left="106" width="334" height="19" font="3">agnosed with liver metastases from colorectal cancer </text>
<text top="708" left="106" width="333" height="19" font="3">can benefit from this therapeutic strategy, due to the </text>
<text top="727" left="106" width="333" height="19" font="3">fact that in certain cases, even after administration of </text>
<text top="746" left="106" width="334" height="19" font="3">systemic chemotherapy, the liver metastases remain </text>
<text top="765" left="106" width="78" height="19" font="3">unresectable</text>
<text top="766" left="184" width="11" height="11" font="7">1-5</text>
<text top="765" left="195" width="4" height="19" font="3">.</text>
<text top="805" left="106" width="9" height="18" font="1">L</text>
<text top="809" left="116" width="28" height="13" font="0">IVER</text>
<text top="805" left="143" width="5" height="18" font="1"> </text>
<text top="809" left="149" width="113" height="13" font="0">TRANSPLANTATION</text>
<text top="805" left="262" width="5" height="18" font="1"> </text>
<text top="809" left="267" width="24" height="13" font="0">FOR</text>
<text top="805" left="291" width="5" height="18" font="1"> </text>
<text top="809" left="297" width="94" height="13" font="0">UNRESECTABLE</text>
<text top="805" left="391" width="5" height="18" font="1"> </text>
<text top="827" left="106" width="77" height="13" font="0">COLORECTAL</text>
<text top="824" left="183" width="5" height="18" font="1"> </text>
<text top="827" left="189" width="79" height="13" font="0">METASTASES</text>
<text top="859" left="136" width="303" height="19" font="3">Interestingly, two of the first seven reported liver </text>
<text top="878" left="106" width="334" height="19" font="3">transplantation procedures had been performed for </text>
<text top="897" left="106" width="321" height="19" font="3">unresectable liver metastases from colorectal cancer</text>
<text top="897" left="427" width="5" height="11" font="7">6</text>
<text top="897" left="432" width="8" height="19" font="3">; </text>
<text top="916" left="106" width="330" height="19" font="3">however, at that time the results were rather discour-</text>
<text top="934" left="106" width="334" height="19" font="3">aging, the method not being considered as a viable </text>
<text top="953" left="106" width="333" height="19" font="3">strategy of treatment at that moment. For example, in </text>
<text top="972" left="106" width="333" height="19" font="3">the paper published by Graeme Poston in 2004, liver </text>
<text top="991" left="106" width="334" height="19" font="3">transplantation was considered as an inappropriate </text>
<text top="1010" left="106" width="334" height="19" font="3">method of treatment for such cases due to the high </text>
<text top="1029" left="106" width="333" height="19" font="3">rates of recurrence, mainly explained by the necessity </text>
<text top="1048" left="106" width="322" height="19" font="3">of using a large amount of immunosuppressive drugs</text>
<text top="1048" left="428" width="5" height="11" font="7">7</text>
<text top="1048" left="432" width="4" height="19" font="3">.</text>
<text top="1066" left="136" width="300" height="19" font="3">However, during the further period, the man-</text>
<text top="1085" left="106" width="329" height="19" font="3">agement of liver transplanted patients was submit-</text>
<text top="1104" left="106" width="335" height="19" font="3">ted to permanent modifications, and the overall </text>
<text top="1123" left="106" width="335" height="19" font="3">survival improved; the operative techniques have </text>
<text top="1142" left="106" width="334" height="19" font="3">been well standardised while the pharmacokinetics </text>
<text top="277" left="457" width="334" height="19" font="3">of immunosuppressive treatment of choice has been </text>
<text top="296" left="457" width="329" height="19" font="3">better understood, rendering liver transplanta-</text>
<text top="315" left="457" width="330" height="19" font="3">tion into a safer and more effective surgical thera-</text>
<text top="334" left="457" width="86" height="19" font="3">peutic option</text>
<text top="334" left="543" width="23" height="11" font="7">6,8-11</text>
<text top="334" left="567" width="225" height="19" font="3">; for instance, the European Liver </text>
<text top="352" left="457" width="333" height="19" font="3">Transplantation Registry reported in 2007 an overall </text>
<text top="371" left="457" width="334" height="19" font="3">one year and five year survival rate of 85% and 74% </text>
<text top="390" left="457" width="334" height="19" font="3">respectively, demonstrating the safety as well as the </text>
<text top="409" left="457" width="140" height="19" font="3">efficacy of the method</text>
<text top="409" left="597" width="9" height="11" font="7">12</text>
<text top="409" left="606" width="4" height="19" font="3">.</text>
<text top="428" left="487" width="304" height="19" font="3">Therefore, later on the method was reanalysed </text>
<text top="446" left="457" width="335" height="19" font="3">and better results were reported in patients with </text>
<text top="465" left="457" width="334" height="19" font="3">unresectable colorectal liver metastases. Moreover, </text>
<text top="484" left="457" width="334" height="19" font="3">once the imagistic techniques improved, the rate of </text>
<text top="503" left="457" width="330" height="19" font="3">detection of the extrahepatic disease significantly im-</text>
<text top="522" left="457" width="334" height="19" font="3">proved, and therefore a better identification of the </text>
<text top="540" left="457" width="298" height="19" font="3">candidates for liver transplantation was feasible</text>
<text top="541" left="754" width="9" height="11" font="7">13</text>
<text top="540" left="763" width="4" height="19" font="3">.</text>
<text top="559" left="487" width="300" height="19" font="3">In consequence, the method has been recon-</text>
<text top="578" left="457" width="335" height="19" font="3">sidered, being applied with encouraging results in </text>
<text top="597" left="457" width="335" height="19" font="3">certain cases presenting unresectable, but limited </text>
<text top="616" left="457" width="122" height="19" font="3">to the liver disease</text>
<text top="616" left="579" width="5" height="11" font="7">3</text>
<text top="616" left="584" width="207" height="19" font="3">. However, at this moment, the </text>
<text top="634" left="457" width="329" height="19" font="3">method is not recommended as a standard therapeu-</text>
<text top="653" left="457" width="335" height="19" font="3">tic strategy, not being included in the therapeutic </text>
<text top="672" left="457" width="334" height="19" font="3">guidelines. The lack of enthusiasm which has been </text>
<text top="691" left="457" width="333" height="19" font="3">demonstrated by certain liver transplantation centres </text>
<text top="709" left="457" width="333" height="19" font="3">when it comes to the introduction of this method as </text>
<text top="728" left="457" width="329" height="19" font="3">part of the standard treatment in patients with unre-</text>
<text top="747" left="457" width="333" height="19" font="3">sectable liver metastases from colorectal origin can </text>
<text top="766" left="457" width="329" height="19" font="3">be explained by the low number of donors that pro-</text>
<text top="785" left="457" width="333" height="19" font="3">hibits a wide use of the method in a patient in whom </text>
<text top="803" left="457" width="334" height="19" font="3">the oncological outcome cannot be presumed. Even </text>
<text top="822" left="457" width="335" height="19" font="3">if the patient presents at a certain moment of the </text>
<text top="841" left="457" width="334" height="19" font="3">evolution exclusively liver-related metastatic disease, </text>
<text top="860" left="457" width="334" height="19" font="3">the oncological outcomes after liver transplantation </text>
<text top="879" left="457" width="333" height="19" font="3">are hard to be anticipated, especially due to the fact </text>
<text top="897" left="457" width="329" height="19" font="3">that postoperatively he should be submitted to an ag-</text>
<text top="916" left="457" width="334" height="19" font="3">gressive immunosuppressive treatment which might </text>
<text top="935" left="457" width="302" height="19" font="3">favour the development of a systemic recurrence</text>
<text top="936" left="758" width="9" height="11" font="7">14</text>
<text top="935" left="767" width="4" height="19" font="3">.</text>
<text top="954" left="487" width="303" height="19" font="3">An interesting study which compared the results </text>
<text top="973" left="457" width="333" height="19" font="3">provided by chemotherapy as a single therapeutic </text>
<text top="991" left="457" width="329" height="19" font="3">option to those reported after neoadjuvant chemo-</text>
<text top="1010" left="457" width="335" height="19" font="3">therapy and liver transplantation for unresectable </text>
<text top="1029" left="457" width="334" height="19" font="3">liver metastases with colorectal origin demonstrated </text>
<text top="1048" left="457" width="335" height="19" font="3">a five years survival rate of 9% for the first group </text>
<text top="1067" left="457" width="329" height="19" font="3">versus 56% in the second group, underlying the ben-</text>
<text top="1085" left="457" width="329" height="19" font="3">efits of the surgical method. The study was a mul-</text>
<text top="1104" left="457" width="334" height="19" font="3">ticentric one, conducted in the Northern European </text>
<text top="1123" left="457" width="334" height="19" font="3">countries and included 21 cases submitted to liver </text>
<text top="1142" left="457" width="334" height="19" font="3">transplantation and 47 cases submitted to first line </text>
<text top="126" left="457" width="329" height="19" font="3">pour le traitement des métasta   ses hépatiques inopé-</text>
<text top="145" left="457" width="170" height="19" font="3">rables du cancer colorectal.</text>
<text top="186" left="457" width="81" height="16" font="4">Mots-clés: </text>
<text top="182" left="541" width="245" height="19" font="3">tumeur colorectale, métastases hépa-</text>
<text top="201" left="457" width="335" height="19" font="3">tiques, lésions extrahépatiques, transplantation du </text>
<text top="220" left="457" width="26" height="19" font="3">foie.</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1262" width="892">
<text top="91" left="106" width="607" height="14" font="9">Liver transplantation for unresectable hepatic metastases from colorectal cancer... – BACALBASA et al</text>
<text top="1182" left="106" width="143" height="14" font="9">332  /  vol. 54, no. 2</text>
<text top="126" left="106" width="329" height="19" font="3">chemotherapy; although the progression free sur-</text>
<text top="145" left="106" width="334" height="19" font="3">vival interval was similar between the two groups (8 </text>
<text top="164" left="106" width="334" height="19" font="3">months versus 10 months), a dramatic difference in </text>
<text top="183" left="106" width="293" height="19" font="3">terms of the overall survival was demonstrated</text>
<text top="183" left="399" width="9" height="11" font="7">15</text>
<text top="183" left="408" width="4" height="19" font="3">.</text>
<text top="223" left="106" width="11" height="18" font="1">S</text>
<text top="226" left="117" width="43" height="13" font="0">TUDIES</text>
<text top="223" left="160" width="5" height="18" font="1"> </text>
<text top="226" left="166" width="69" height="13" font="0">REPORTING</text>
<text top="223" left="235" width="5" height="18" font="1"> </text>
<text top="226" left="240" width="23" height="13" font="0">THE</text>
<text top="223" left="263" width="5" height="18" font="1"> </text>
<text top="226" left="269" width="72" height="13" font="0">FEASIBILITY</text>
<text top="223" left="341" width="5" height="18" font="1"> </text>
<text top="226" left="347" width="25" height="13" font="0">AND</text>
<text top="223" left="372" width="5" height="18" font="1"> </text>
<text top="226" left="378" width="45" height="13" font="0">SAFETY</text>
<text top="223" left="423" width="5" height="18" font="1"> </text>
<text top="245" left="106" width="15" height="13" font="0">OF</text>
<text top="241" left="122" width="5" height="18" font="1"> </text>
<text top="245" left="127" width="34" height="13" font="0">LIVER</text>
<text top="241" left="161" width="5" height="18" font="1"> </text>
<text top="245" left="167" width="113" height="13" font="0">TRANSPLANTATION</text>
<text top="241" left="280" width="5" height="18" font="1"> </text>
<text top="245" left="286" width="24" height="13" font="0">FOR</text>
<text top="241" left="310" width="5" height="18" font="1"> </text>
<text top="245" left="315" width="94" height="13" font="0">UNRESECTABLE</text>
<text top="241" left="409" width="5" height="18" font="1"> </text>
<text top="264" left="106" width="34" height="13" font="0">LIVER</text>
<text top="260" left="140" width="5" height="18" font="1"> </text>
<text top="264" left="146" width="79" height="13" font="0">METASTASES</text>
<text top="260" left="225" width="5" height="18" font="1"> </text>
<text top="264" left="231" width="35" height="13" font="0">FROM</text>
<text top="260" left="266" width="5" height="18" font="1"> </text>
<text top="264" left="271" width="77" height="13" font="0">COLORECTAL</text>
<text top="260" left="348" width="5" height="18" font="1"> </text>
<text top="264" left="354" width="49" height="13" font="0">CANCER</text>
<text top="295" left="136" width="303" height="19" font="3">The first studies that took into consideration the </text>
<text top="314" left="106" width="333" height="19" font="3">idea of liver transplantation for unresectable, limited </text>
<text top="333" left="106" width="333" height="19" font="3">to liver colorectal cancer metastases came from Adam </text>
<text top="352" left="106" width="334" height="19" font="8"><i>et al.</i> and were published in 1995; at that moment </text>
<text top="370" left="106" width="334" height="19" font="3">the authors reported a series of 50 cases submitted </text>
<text top="389" left="106" width="333" height="19" font="3">to this therapy, with one year and five year survival </text>
<text top="408" left="106" width="334" height="19" font="3">rates of 62% and 18% respectively; at that moment </text>
<text top="427" left="106" width="335" height="19" font="3">the long-term results were considered rather poor </text>
<text top="446" left="106" width="210" height="19" font="3">and the method was abandoned</text>
<text top="446" left="316" width="9" height="11" font="7">16</text>
<text top="446" left="325" width="115" height="19" font="3">. Further on, the </text>
<text top="464" left="106" width="333" height="19" font="3">method was implemented in Vienna on a group of 25 </text>
<text top="483" left="106" width="333" height="19" font="3">patients, the authors reporting a significant benefit of </text>
<text top="502" left="106" width="330" height="19" font="3">survival, especially in patients who presented nega-</text>
<text top="521" left="106" width="333" height="19" font="3">tive node disease at the time of surgery for the initial </text>
<text top="540" left="106" width="47" height="19" font="3">tumour</text>
<text top="540" left="153" width="9" height="11" font="7">17</text>
<text top="540" left="161" width="278" height="19" font="3">. Initially the Austrian authors proposed the </text>
<text top="558" left="106" width="333" height="19" font="3">method for 25 negative node patients and reported </text>
<text top="577" left="106" width="335" height="19" font="3">one year, three year and five year overall survival </text>
<text top="596" left="106" width="334" height="19" font="3">rates of 76%, 32% and 12%, respectively; later on, </text>
<text top="615" left="106" width="334" height="19" font="3">they found out that 15 out of these cases presented </text>
<text top="634" left="106" width="335" height="19" font="3">micro metastatic disease at the level of the lymph </text>
<text top="652" left="106" width="330" height="19" font="3">nodes and observed that this aspect significantly in-</text>
<text top="671" left="106" width="334" height="19" font="3">fluenced the survival (the overall survival being of </text>
<text top="690" left="106" width="334" height="19" font="3">118 months for patients with negative nodes and 28 </text>
<text top="709" left="106" width="330" height="19" font="3">months for patients presenting micro metastatic de-</text>
<text top="728" left="106" width="90" height="19" font="3">posits, <i>p</i>=0.01)</text>
<text top="728" left="195" width="19" height="11" font="7">17,18</text>
<text top="728" left="215" width="4" height="19" font="3">.</text>
<text top="746" left="136" width="305" height="19" font="3">Liver transplantation for metastatic colorectal </text>
<text top="765" left="106" width="333" height="19" font="3">cancer was widely studied in the Northern European </text>
<text top="784" left="106" width="334" height="19" font="3">Countries due to the presence of a surplus of donor </text>
<text top="803" left="106" width="334" height="19" font="3">organs which was considered as an opportunity to </text>
<text top="822" left="106" width="330" height="19" font="3">explore the borderline indications for transplanta-</text>
<text top="840" left="106" width="334" height="19" font="3">tion. In Norway for example the waiting list for liver </text>
<text top="859" left="106" width="244" height="19" font="3">transplantation is less than one month</text>
<text top="860" left="349" width="9" height="11" font="7">19</text>
<text top="859" left="358" width="4" height="19" font="3">.</text>
<text top="878" left="136" width="300" height="19" font="3">In May 2013, Hagness et al reported their pre-</text>
<text top="897" left="106" width="333" height="19" font="3">liminary experience with regard to the role of liver </text>
<text top="916" left="106" width="333" height="19" font="3">transplantation for liver limited colorectal metastases </text>
<text top="935" left="106" width="153" height="19" font="3">on a group of 21 patients</text>
<text top="935" left="258" width="9" height="11" font="7">19</text>
<text top="934" left="267" width="169" height="19" font="3">. The main criteria of inclu-</text>
<text top="953" left="106" width="333" height="19" font="3">sion in the present prospective study were represented </text>
<text top="972" left="106" width="329" height="19" font="3">by the absence of extrahepatic disease, resected pri-</text>
<text top="991" left="106" width="334" height="19" font="3">mary tumour, and an interval higher than six weeks </text>
<text top="1010" left="106" width="334" height="19" font="3">between the last cycle of chemotherapy and the liver </text>
<text top="1029" left="106" width="333" height="19" font="3">transplantation procedure. After a median follow-up </text>
<text top="1047" left="106" width="333" height="19" font="3">period of 27 months, 33% of cases presented no sign </text>
<text top="1066" left="106" width="334" height="19" font="3">of recurrent disease, the most important prognostic </text>
<text top="1085" left="106" width="333" height="19" font="3">factors after liver transplantation being related to the </text>
<text top="1104" left="106" width="330" height="19" font="3">hepatic tumoral volume at the time of transplanta-</text>
<text top="1123" left="106" width="330" height="19" font="3">tion, to the time from resection of the primary tu-</text>
<text top="1141" left="106" width="334" height="19" font="3">mour to liver transplantation, and to the response </text>
<text top="126" left="457" width="333" height="19" font="3">to chemotherapy, cases presenting progression under </text>
<text top="145" left="457" width="329" height="19" font="3">chemotherapy being associated with a poorer out-</text>
<text top="164" left="457" width="334" height="19" font="3">come. As for the pattern of recurrence, the authors </text>
<text top="183" left="457" width="329" height="19" font="3">mainly reported the development of pulmonary me-</text>
<text top="201" left="457" width="333" height="19" font="3">tastases which were frequently submitted to resection </text>
<text top="220" left="457" width="333" height="19" font="3">with curative intent. The overall survival of the entire </text>
<text top="239" left="457" width="333" height="19" font="3">group was of 95%, 68% and 60% respectively at one </text>
<text top="258" left="457" width="329" height="19" font="3">year, three years and five years follow-up, demonstrat-</text>
<text top="277" left="457" width="329" height="19" font="3">ing similar results when compared to patients submit-</text>
<text top="295" left="457" width="334" height="19" font="3">ted to the classical liver resection of the metastatic </text>
<text top="314" left="457" width="333" height="19" font="3">disease. However, only 35% of cases remained free of </text>
<text top="333" left="457" width="333" height="19" font="3">disease at one-year follow-up, while at the three years </text>
<text top="352" left="457" width="334" height="19" font="3">follow-up all patients experienced recurrent disease. </text>
<text top="371" left="457" width="333" height="19" font="3">In terms of immunosuppressive therapy, in this study, </text>
<text top="389" left="457" width="330" height="19" font="3">mammalian target of rapamycin inhibitor was the op-</text>
<text top="408" left="457" width="333" height="19" font="3">tion of choice and was associated with a rejection rate </text>
<text top="427" left="457" width="334" height="19" font="3">of the graft of 38%, this option remaining therefore </text>
<text top="446" left="457" width="79" height="19" font="3">questionable</text>
<text top="446" left="536" width="9" height="11" font="7">19</text>
<text top="446" left="544" width="4" height="19" font="3">.</text>
<text top="465" left="487" width="305" height="19" font="3">Currently, maybe the most encouraging data </text>
<text top="483" left="457" width="329" height="19" font="3">regarding the role of liver transplantation in this cat-</text>
<text top="502" left="457" width="329" height="19" font="3">egory of patients come from Toso et al and were pub-</text>
<text top="521" left="457" width="89" height="19" font="3">lished in 2017</text>
<text top="522" left="545" width="9" height="11" font="7">20</text>
<text top="521" left="555" width="236" height="19" font="3">. The authors reported the outcomes </text>
<text top="540" left="457" width="333" height="19" font="3">of 12 patients submitted to transplant between 1995 </text>
<text top="559" left="457" width="333" height="19" font="3">and 2015; initially, most often the tumour was staged </text>
<text top="577" left="457" width="333" height="19" font="3">as a T3 one, with a median number of invaded nodes </text>
<text top="596" left="457" width="333" height="19" font="3">of two. At the moment of liver transplantation, the </text>
<text top="615" left="457" width="334" height="19" font="3">median number of liver metastases was nine, most </text>
<text top="634" left="457" width="330" height="19" font="3">patients receiving a neoadjuvant treatment consist-</text>
<text top="653" left="457" width="335" height="19" font="3">ing of irinotecan and oxaliplation; however, none </text>
<text top="671" left="457" width="335" height="19" font="3">of these cases reported disease progression under </text>
<text top="690" left="457" width="334" height="19" font="3">chemotherapy. Liver transplant was performed at a </text>
<text top="709" left="457" width="334" height="19" font="3">median interval of 41 months after surgery for the </text>
<text top="728" left="457" width="330" height="19" font="3">primary tumour and was followed by the administra-</text>
<text top="747" left="457" width="335" height="19" font="3">tion of mammalian target of rapamycin inhibitors. </text>
<text top="765" left="457" width="335" height="19" font="3">The overall post-transplant survival was of 83%, </text>
<text top="784" left="457" width="334" height="19" font="3">62% and 50% at one year, three years and five years </text>
<text top="803" left="457" width="335" height="19" font="3">follow-up respectively, while the median follow-up </text>
<text top="822" left="457" width="334" height="19" font="3">period was of 26 months. During this period, there </text>
<text top="841" left="457" width="334" height="19" font="3">were six cases of recurrent disease developed at the </text>
<text top="859" left="457" width="333" height="19" font="3">level of lungs (in five cases), liver (in three cases) and </text>
<text top="878" left="457" width="155" height="19" font="3">peritoneum (in one case)</text>
<text top="879" left="612" width="9" height="11" font="7">20</text>
<text top="878" left="621" width="4" height="19" font="3">.</text>
<text top="897" left="487" width="303" height="19" font="3">Recently, a study conducted in Louvain, Belgium, </text>
<text top="916" left="457" width="334" height="19" font="3">demonstrated the feasibility of living related to liver </text>
<text top="935" left="457" width="333" height="19" font="3">transplant  in  patients  with  colorectal  cancer  and </text>
<text top="953" left="457" width="330" height="19" font="3">liver metastases; in the present study, the authors in-</text>
<text top="972" left="457" width="333" height="19" font="3">cluded 64 cases submitted to living related transplant </text>
<text top="991" left="457" width="329" height="19" font="3">between 1998 and 2016, two of them being submit-</text>
<text top="1010" left="457" width="329" height="19" font="3">ted to liver transplantation for unresectable colorec-</text>
<text top="1029" left="457" width="334" height="19" font="3">tal liver metastases. One case received a right hemi </text>
<text top="1047" left="457" width="333" height="19" font="3">liver graft, while the second one received a left graft; </text>
<text top="1066" left="457" width="330" height="19" font="3">the authors reported that the main complications en-</text>
<text top="1085" left="457" width="329" height="19" font="3">countered in the recipients were the biliary and vas-</text>
<text top="1104" left="457" width="333" height="19" font="3">cular ones, while three patients developed a small for </text>
<text top="1123" left="457" width="330" height="19" font="3">size syndrome; however, the morbidity was not cor-</text>
<text top="1141" left="457" width="306" height="19" font="3">related to the indication for liver transplantation</text>
<text top="1142" left="764" width="9" height="11" font="7">21</text>
<text top="1141" left="772" width="4" height="19" font="3">.</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="10" size="11" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="9">Archives of the Balkan Medical Union</text>
<text top="1182" left="660" width="42" height="14" font="9">June </text>
<text top="1182" left="693" width="94" height="14" font="9">2019 / 333</text>
<text top="126" left="106" width="12" height="18" font="1">C</text>
<text top="130" left="118" width="77" height="13" font="0">ONCLUSIONS</text>
<text top="161" left="136" width="300" height="19" font="3">Liver transplant seem to be a promising thera-</text>
<text top="180" left="106" width="334" height="19" font="3">peutic strategy for patients presenting unresectable, </text>
<text top="199" left="106" width="333" height="19" font="3">confined to liver colorectal metastases. Improvement </text>
<text top="217" left="106" width="334" height="19" font="3">of the imaging techniques (in order to exclude the </text>
<text top="236" left="106" width="335" height="19" font="3">presence of extrahepatic disease), of the surgical </text>
<text top="255" left="106" width="334" height="19" font="3">techniques, as well as a better understanding of the </text>
<text top="274" left="106" width="334" height="19" font="3">pharmacokinetics and of the mechanisms of action </text>
<text top="292" left="106" width="334" height="19" font="3">of different types of immunosuppressive treatment </text>
<text top="311" left="106" width="333" height="19" font="3">were crucial in order to obtain better results in terms </text>
<text top="330" left="106" width="334" height="19" font="3">of survival. However, the method is not part of the </text>
<text top="349" left="106" width="335" height="19" font="3">standard therapeutic guidelines for the moment, </text>
<text top="367" left="106" width="334" height="19" font="3">probably due to the low number of donors. Further </text>
<text top="386" left="106" width="329" height="19" font="3">prospective studies are still needed in order to pro-</text>
<text top="405" left="106" width="333" height="19" font="3">vide a better identification of the patients who could </text>
<text top="424" left="106" width="281" height="19" font="3">benefit most from this therapeutic approach.</text>
<text top="484" left="106" width="267" height="15" font="4">Compliance with Ethics Requirements:</text>
<text top="499" left="136" width="304" height="19" font="8"><i>„The authors declare no conflict of interest regarding </i></text>
<text top="517" left="106" width="65" height="19" font="8"><i>this article“</i></text>
<text top="557" left="106" width="12" height="18" font="1">R</text>
<text top="561" left="118" width="71" height="13" font="0">EFERENCES</text>
<text top="592" left="106" width="334" height="15" font="9">1.  American Cancer Society. Cancer Facts &amp; Figures 2017. </text>
<text top="608" left="128" width="235" height="15" font="9">Atlanta, Ga: American Cancer Society; 2017.</text>
<text top="624" left="106" width="329" height="15" font="9">2.  Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemo-</text>
<text top="639" left="128" width="311" height="15" font="9">therapy before liver resection for patients with unresectable </text>
<text top="655" left="128" width="311" height="15" font="9">liver metastases from colorectal carcinoma. <i>J Clin Oncol.</i> </text>
<text top="671" left="128" width="120" height="15" font="9">2005; 23(9):2038-2048.</text>
<text top="687" left="106" width="332" height="15" font="9">3.  Chakedis J, Squires MH, Beal EW, et al. Update on current </text>
<text top="702" left="128" width="311" height="15" font="9">problems in colorectal liver metastasis. <i>Curr Probl Surg.</i> 2017; </text>
<text top="718" left="128" width="81" height="15" font="9">54(11):554-602.</text>
<text top="734" left="106" width="335" height="15" font="9">4.  Mohammad WM, Balaa FK. Surgical management of </text>
<text top="750" left="128" width="313" height="15" font="9">colorectal liver metastases. <i>Clin Colon Rectal Surg</i>. 2009; </text>
<text top="765" left="128" width="73" height="15" font="9">22(4):225-232.</text>
<text top="781" left="106" width="329" height="15" font="9">5.  Nathan H, de Jong MC, Pulitano C, et al. Conditional sur-</text>
<text top="797" left="128" width="311" height="15" font="9">vival after surgical resection of colorectal liver metastasis: an </text>
<text top="813" left="128" width="311" height="15" font="9">international multi-institutional analysis of 949 patients. <i>J </i></text>
<text top="828" left="128" width="180" height="15" font="10"><i>Am Coll Surg. </i>2010; 210(5):755-756.</text>
<text top="126" left="457" width="329" height="15" font="9">6.  Starzl TE. The saga of liver replacement, with particular ref-</text>
<text top="142" left="478" width="308" height="15" font="9">erence to the reciprocal influence of liver and kidney trans-</text>
<text top="158" left="478" width="308" height="15" font="9">plantation (1955-1967). <i>J Am Coll Surg.</i> 2002; 195(5):587-610.</text>
<text top="173" left="457" width="332" height="15" font="9">7.  Poston GJ. Surgical strategies for colorectal liver metastases. </text>
<text top="189" left="478" width="174" height="15" font="10"><i>Surg Oncol.</i> 2004; 13(2-3):125-136.</text>
<text top="205" left="457" width="333" height="15" font="9">8.  Chan SC, Lo CM, Fan ST. Simplifying living donor liver </text>
<text top="221" left="478" width="308" height="15" font="9">transplantation. <i>Hepatobiliary Pancreat Dis Int.</i> 2010;9(1):9-14.</text>
<text top="236" left="457" width="332" height="15" font="9">9.  Chan SC, Fan ST, Lo CM, Liu CL, Wong J. Toward current </text>
<text top="252" left="478" width="312" height="15" font="9">standards of donor right hepatectomy for adult-to-adult live </text>
<text top="268" left="478" width="312" height="15" font="9">donor liver transplantation through the experience of 200 </text>
<text top="284" left="478" width="187" height="15" font="9">cases. <i>Ann Surg.</i> 2007;245(1):110-117.</text>
<text top="299" left="457" width="332" height="15" font="9">10.  Hwang S, Lee SG, Lee YJ, et al. Lessons learned from 1,000 </text>
<text top="315" left="478" width="311" height="15" font="9">living donor liver transplantations in a single center: how to </text>
<text top="331" left="478" width="308" height="15" font="9">make living donations safe. <i>Liver Transpl.</i> 2006;12(6):920-927.</text>
<text top="347" left="457" width="334" height="15" font="9">11.  Chan SC, Fan ST, Lo CM et al. A decade of right liver </text>
<text top="362" left="478" width="308" height="15" font="9">adult-to-adult living donor liver transplantation: the recipi-</text>
<text top="378" left="478" width="286" height="15" font="9">ent mid-term outcomes. <i>Ann Surg</i>. 2008;248(3):411-419.</text>
<text top="394" left="457" width="333" height="15" font="9">12.  European Liver Transplant Registry: Data analysis booklet. </text>
<text top="410" left="478" width="233" height="15" font="9">Paris: 2007. Available at: http://www.eltr.org</text>
<text top="425" left="457" width="332" height="15" font="9">13.  Zhu JQ, He Q, Li XL. Liver transplantation benefits selected </text>
<text top="441" left="478" width="311" height="15" font="9">patients with hilar cholangiocarcinoma and colorectal liver </text>
<text top="457" left="478" width="308" height="15" font="9">metastases. <i>Hepatobiliary Pancreat Dis Int.</i> 2018;17(5):385-386.</text>
<text top="473" left="457" width="333" height="15" font="9">14.  Chan A. Liver transplantation for unresectable colorectal </text>
<text top="488" left="478" width="301" height="15" font="9">liver metastasis. <i>Hepatobiliary Surg Nutr.</i> 2013;2(3):162-164.</text>
<text top="504" left="457" width="333" height="15" font="9">15.  Dueland S, Guren TK, Hagness M et al. Chemotherapy or </text>
<text top="520" left="478" width="311" height="15" font="9">liver transplantation for nonresectable liver metastases from </text>
<text top="536" left="478" width="255" height="15" font="9">colorectal cancer? <i>Ann Surg.</i> 2015;261(5):956-960.</text>
<text top="551" left="457" width="334" height="15" font="9">16. Hoti E, Adam R. Liver transplantation for primary and </text>
<text top="567" left="478" width="302" height="15" font="9">metastatic liver cancers. <i>Transpl Int. </i>2008;21(12):1107-1117.</text>
<text top="583" left="457" width="329" height="15" font="9">17.  Kappel S, Kandioler D, Steininger R, et al. Genetic detec-</text>
<text top="599" left="478" width="312" height="15" font="9">tion of lymph node micrometastases: a selection criterion </text>
<text top="614" left="478" width="312" height="15" font="9">for liver transplantation in patients with liver metastases </text>
<text top="630" left="478" width="294" height="15" font="9">after colorectal cancer. <i>Transplantation.</i> 2006;81(1):64-70.</text>
<text top="646" left="457" width="333" height="15" font="9">18.  Muhlbacher F, Huk I, Steininger R, et al. Is orthotopic liver </text>
<text top="662" left="478" width="311" height="15" font="9">transplantation a feasible treatment for secondary cancer of </text>
<text top="677" left="478" width="268" height="15" font="9">the liver? <i>Transplant Proc.</i> 1991;23(1 Pt 2):1567-1568.</text>
<text top="693" left="457" width="332" height="15" font="9">19.  Hagness M, Foss A, Line PD, et al. Liver transplantation for </text>
<text top="709" left="478" width="311" height="15" font="9">nonresectable liver metastases from colorectal cancer. <i>Ann </i></text>
<text top="725" left="478" width="138" height="15" font="10"><i>Surg.</i> 2013;257(5):800-806.</text>
<text top="740" left="457" width="332" height="15" font="9">20.  Toso C, Pinto MH, Andres A, et al. Liver transplantation for </text>
<text top="756" left="478" width="312" height="15" font="9">colorectal liver metastasis: Survival without recurrence can </text>
<text top="772" left="478" width="248" height="15" font="9">be achieved. <i>Liver Transpl</i>. 2017;23(8):1073-1076.</text>
<text top="788" left="457" width="329" height="15" font="9">21.  Iesari S, Inostroza Nunez ME, Rico Juri JM, et al. Adult-</text>
<text top="803" left="478" width="308" height="15" font="9">to-adult living-donor liver transplantation: The experi-</text>
<text top="819" left="478" width="311" height="15" font="9">ence of the Universite catholique de Louvain. <i>Hepatobiliary </i></text>
<text top="835" left="478" width="184" height="15" font="10"><i>Pancreat Dis Int</i>. 2019;18(2):132-142.</text>
</page>
</pdf2xml>
